NASDAQ:FTSV - Forty Seven Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$14.47 -0.73 (-4.80 %)
(As of 01/18/2019 04:00 PM ET)
Previous Close$14.47
Today's Range$14.31 - $15.5199
52-Week Range$12.02 - $23.83
Volume126,125 shs
Average Volume201,329 shs
Market Capitalization$472.18 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Forty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; and FSI-189, an antibody that binds to SIRPa for the treatment of solid tumors. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.

Receive FTSV News and Ratings via Email

Sign-up to receive the latest news and ratings for FTSV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FTSV
CUSIPN/A
Phone650-352-4150

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees46
Market Cap$472.18 million
OptionableNot Optionable

Forty Seven (NASDAQ:FTSV) Frequently Asked Questions

What is Forty Seven's stock symbol?

Forty Seven trades on the NASDAQ under the ticker symbol "FTSV."

How were Forty Seven's earnings last quarter?

Forty Seven Inc (NASDAQ:FTSV) released its quarterly earnings data on Tuesday, November, 13th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.54) by $0.17. View Forty Seven's Earnings History.

When is Forty Seven's next earnings date?

Forty Seven is scheduled to release their next quarterly earnings announcement on Tuesday, February 12th 2019. View Earnings Estimates for Forty Seven.

What price target have analysts set for FTSV?

6 brokerages have issued 12-month price objectives for Forty Seven's stock. Their predictions range from $21.00 to $36.00. On average, they anticipate Forty Seven's stock price to reach $27.3333 in the next year. This suggests a possible upside of 88.9% from the stock's current price. View Analyst Price Targets for Forty Seven.

What is the consensus analysts' recommendation for Forty Seven?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Forty Seven in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Forty Seven.

What are Wall Street analysts saying about Forty Seven stock?

Here are some recent quotes from research analysts about Forty Seven stock:
  • 1. According to Zacks Investment Research, "Forty Seven, Inc. is a clinical-stage immuno-oncology company. It focused on developing novel checkpoint therapies to activate macrophages in the fight against cancer. The company's product candidate consists of 5F9, is an IgG4 monoclonal antibody against CD47 which is designed to interfere with recognition of CD47 by the SIRP? receptor on macrophages. Forty Seven, Inc. is based in CA, United States. " (1/15/2019)
  • 2. HC Wainwright analysts commented, "We maintain our Buy rating on FTSV and our 12-month price target of $21.00 per share. We derive our price target based on a risk-based NPV (rNPV) analysis of projected 5F9 revenues through 2030 assuming a 12% discount rate and 3% terminal growth rate. We derive rNPV of $975M for 5F9 and add in cash, cash equivalents, and short-term investments of $154M to arrive at a 12-month price target of $20.79 per diluted share, which we round to $21.00." (1/14/2019)

Has Forty Seven been receiving favorable news coverage?

Headlines about FTSV stock have trended somewhat positive on Saturday, InfoTrie reports. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Forty Seven earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave news stories about the company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term.

Are investors shorting Forty Seven?

Forty Seven saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 930,394 shares, an increase of 59.7% from the December 14th total of 582,614 shares. Based on an average trading volume of 274,441 shares, the short-interest ratio is currently 3.4 days. Approximately 7.0% of the shares of the stock are short sold. View Forty Seven's Current Options Chain.

Who are some of Forty Seven's key competitors?

Who are Forty Seven's key executives?

Forty Seven's management team includes the folowing people:
  • Dr. Mark A. McCamish, Pres, CEO & Director (Age 65)
  • Dr. Craig S. Gibbs, Chief Bus. Officer (Age 55)
  • Dr. Chris H. Takimoto M.D., Ph.D., Chief Medical Officer (Age 59)
  • Mr. Mark Chao, Founder & VP of Clinical Devel.
  • Mr. Jens-Peter Volkmer, Founder and VP of Research & Early Devel.

When did Forty Seven IPO?

(FTSV) raised $100 million in an IPO on Thursday, June 28th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity, BTIG and Oppenheimer were co-managers.

When did the company's lock-up period expire?

Forty Seven's lock-up period expired on Tuesday, December 25th. Forty Seven had issued 7,035,000 shares in its public offering on June 28th. The total size of the offering was $112,560,000 based on an initial share price of $16.00. Since the end of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.

Who are Forty Seven's major shareholders?

Forty Seven's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Bourgeon Capital Management LLC (1.40%) and Virtu Financial LLC (0.03%). Company insiders that own Forty Seven stock include Chris H Takimoto, Christopher J Schaepe, Irving Weissman, Lifesciences Iii LP Clarus, Mark Anthony Mccamish, Peter Nieh, Ravi Mhatre, Ravindra Majeti and Stefan A Dyckerhoff. View Institutional Ownership Trends for Forty Seven.

Which institutional investors are buying Forty Seven stock?

FTSV stock was acquired by a variety of institutional investors in the last quarter, including Bourgeon Capital Management LLC and Virtu Financial LLC. Company insiders that have bought Forty Seven stock in the last two years include Christopher J Schaepe, Lifesciences Iii LP Clarus, Peter Nieh, Ravi Mhatre and Stefan A Dyckerhoff. View Insider Buying and Selling for Forty Seven.

How do I buy shares of Forty Seven?

Shares of FTSV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Forty Seven's stock price today?

One share of FTSV stock can currently be purchased for approximately $14.47.

How big of a company is Forty Seven?

Forty Seven has a market capitalization of $472.18 million. Forty Seven employs 46 workers across the globe.

What is Forty Seven's official website?

The official website for Forty Seven is http://www.fortyseveninc.com.

How can I contact Forty Seven?

Forty Seven's mailing address is 1490 O`BRIEN DRIVE SUITE A, MENLO PARK CA, 94025. The company can be reached via phone at 650-352-4150 or via email at [email protected]


MarketBeat Community Rating for Forty Seven (NASDAQ FTSV)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  48 (Vote Outperform)
Underperform Votes:  51 (Vote Underperform)
Total Votes:  99
MarketBeat's community ratings are surveys of what our community members think about Forty Seven and other stocks. Vote "Outperform" if you believe FTSV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FTSV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/19/2019 by MarketBeat.com Staff

Featured Article: Quiet Period

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel